MedTrace Logo

A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

NCT06771479 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-10-03

No results posted yet for this study

Summary

This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.

Conditions

  • Monkeypox

Interventions

BIOLOGICAL

MVA strain monkeypox attenuated live vaccine (low dose)

Low dose MVA strain monkeypox attenuated live vaccine

BIOLOGICAL

MVA strain monkeypox attenuated live vaccine (high dose)

High dose MVA strain monkeypox attenuated live vaccine

OTHER

Placebo

Vaccine excipient

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Shuang Li, Master · Henan Infectious Disease Hospital

  • Qingxia zhao, Bachelor · Henan Infectious Disease Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-22
Primary Completion
2026-01-30
Completion
2026-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06771479 on ClinicalTrials.gov